<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474888</url>
  </required_header>
  <id_info>
    <org_study_id>1508058</org_study_id>
    <secondary_id>2015-001807-29</secondary_id>
    <nct_id>NCT02474888</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis</brief_title>
  <acronym>MONITUX</acronym>
  <official_title>Pharmacokinetic Study of Rituximab Induction Regimen in ANCA-associated Vasculitis : a Predictive Factor of Clinical Outcome? (MONITUX)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Theradiag</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the investigators' study is to evaluate whether monitoring serum rituximab levels&#xD;
      could be an interesting tool in the follow-up of ANCA-associated vasculitis patients.&#xD;
&#xD;
      All consecutive patients, hospitalized for a new diagnosis of ANCA-associated vasculitis or&#xD;
      the relapse of a known ANCA-associated vasculitis, in which the decision to start an&#xD;
      induction regimen with rituximab has been taken, will be included.&#xD;
&#xD;
      Serum rituximab levels (along with serum anti-rituximab antibodies levels) will be determined&#xD;
      (at M+1 and M+3) and the correlation with clinical outcome at M+6 will be analyzed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    failure of recruit&#xD;
  </why_stopped>
  <start_date type="Actual">September 15, 2015</start_date>
  <completion_date type="Actual">June 12, 2020</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>serum rituximab levels</measure>
    <time_frame>1 month after stop of rituximab induction regimen</time_frame>
    <description>rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0, 6 months after stop of induction regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>serum rituximab levels</measure>
    <time_frame>3 months after stop of rituximab induction regimen</time_frame>
    <description>rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum rituximab levels</measure>
    <time_frame>6 months after stop of rituximab induction regimen</time_frame>
    <description>rituximab level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum anti-rituximab antibodies</measure>
    <time_frame>1 month after stop of rituximab induction regimen</time_frame>
    <description>serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum anti-rituximab antibodies</measure>
    <time_frame>3 months after stop of rituximab induction regimen</time_frame>
    <description>serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum anti-rituximab antibodies</measure>
    <time_frame>6 months after stop of rituximab induction regimen</time_frame>
    <description>serum anti-rituximab antibodies level comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum B lymphocytes (CD19+ cells) levels</measure>
    <time_frame>1 month after stop of rituximab induction regimen</time_frame>
    <description>Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum B lymphocytes (CD19+ cells) levels</measure>
    <time_frame>3 months after stop of rituximab induction regimen</time_frame>
    <description>Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum B lymphocytes (CD19+ cells) levels</measure>
    <time_frame>6 months after stop of rituximab induction regimen</time_frame>
    <description>Serum B lymphocytes (CD19+ cells) levels comparison between number of non-responders and number of responders after rituximab induction regimen. The number of non-responders is defined by a Birmingham Vascularitis Activity score &gt; 0 six months after stop of induction regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient number with adverse event</measure>
    <time_frame>from start of induction rituximab regimen until six monthes after stop of induction regimen</time_frame>
    <description>frequency and nature of rituximab-attributed adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">28</enrollment>
  <condition>Granulomatosis, Wegener's</condition>
  <condition>Microscopic Polyangiitis</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <description>a classical induction regimen with rituximab (decision taken before inclusion), implying an infusion of 375mg/mÂ² per week, for 4 consecutive weeks (from week -3 until week 0) with blood specimen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood specimen</intervention_name>
    <description>blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment</description>
    <arm_group_label>Rituximab</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood specimen for serum rituximab level and serum anti-rituximab level&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill&#xD;
        criterions), with or without detectable ANCA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Granulomatosis with polyangiitis or microscopic polyangiitis (according to Chapel Hill&#xD;
             criterions), with or without detectable ANCA&#xD;
&#xD;
          -  Decision taken to start an induction regimen with rituximab&#xD;
&#xD;
          -  Informed and having signed the study consent form&#xD;
&#xD;
          -  If of child-bearing potential, female patients will have use an effective method of&#xD;
             contraception during RTX (rituximab) treatment and in the 12 months following RTX&#xD;
             treatment stop&#xD;
&#xD;
          -  no-breast-feeding during RTX treatment and in the 12 months following RTX treatment&#xD;
             stop&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other primary or secondary systemic vasculitis&#xD;
&#xD;
          -  Incapacity or refusal to sign the informed consent form&#xD;
&#xD;
          -  Incapacity or refusal to adhere to treatment or perform the follow-up examinations&#xD;
             required by the study&#xD;
&#xD;
          -  Allergy, documented hypersensitivity or contraindication to the medications used in&#xD;
             the present study (corticosteroids, rituximab)&#xD;
&#xD;
          -  severe active infection&#xD;
&#xD;
          -  Patient with severe heart failure (stage NYHA IV) or any other unstable heart disease&#xD;
             Pregnancy, except for cases where the expected benefit oj treatment seems to surpass&#xD;
             the potential risks&#xD;
&#xD;
          -  Patients with active hepatitis B&#xD;
&#xD;
          -  Any live vaccine within four weeks prior to the first infusion of RTX&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pascal CATHEBRAS, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Saint-Etienne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HÃ´pital Edouard Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HÃ´pital de la Croix Rousse</name>
      <address>
        <city>Lyon</city>
        <zip>69317</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint-Etienne</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 10, 2015</study_first_submitted>
  <study_first_submitted_qc>June 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Granulomatosis with Polyangiitis</mesh_term>
    <mesh_term>Microscopic Polyangiitis</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

